StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/305% below fair value
$2.83+0.10 (+3.86%)

Close on Nov 18, 2026Market cap $1.51BP/E –Yield –

Recursion Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Recursion Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$352.27M. For fiscal 2025 it was -$378.28M. The highest annual figure on record is -$51.23M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$378.28M–
FY2024Dec 31, 2024-$372.87M–
FY2023Dec 31, 2023-$299.74M–
FY2022Dec 31, 2022-$120.58M–
FY2021Dec 31, 2021-$198.41M–
FY2020Dec 31, 2020-$51.23M–
FY2019Dec 31, 2019-$60.95M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$105.99M–
Q1 FY2026Mar 31, 2026-$81.36M–
Q4 FY2025Dec 31, 2025-$47.32M–
Q3 FY2025Sep 30, 2025-$117.60M–
Q2 FY2025Jun 30, 2025-$79.57M–
Q1 FY2025Mar 31, 2025-$133.79M–
Q4 FY2024Dec 31, 2024-$116.73M–
Q3 FY2024Sep 30, 2024-$63.79M–
Q2 FY2024Jun 30, 2024-$83.40M–
Q1 FY2024Mar 31, 2024-$108.95M–
Q4 FY2023Dec 31, 2023-$76.14M–
Q3 FY2023Sep 30, 2023-$73.67M–
Q2 FY2023Jun 30, 2023-$71.44M–
Q1 FY2023Mar 31, 2023-$78.49M-207.5%
Q4 FY2022Dec 31, 2022-$52.73M–
Q3 FY2022Sep 30, 2022-$62.80M–
Q2 FY2022Jun 30, 2022-$78.10M–
Q1 FY2022Mar 31, 2022$73.05M–
Q4 FY2021Dec 31, 2021-$65.62M-1443.1%
Q3 FY2021Sep 30, 2021-$42.75M–
Q2 FY2021Jun 30, 2021-$39.87M–
Q1 FY2021Mar 31, 2021-$50.17M–
Q4 FY2020Dec 31, 2020$4.89M–
Q3 FY2020Sep 30, 2020-$20.28M–
Q2 FY2020Jun 30, 2020-$17.33M–
Q1 FY2020Mar 31, 2020-$18.50M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?